Rivenprost

DB16315InvestigationalSmall molecule

Rivenprost is under investigation in clinical trial NCT00296556 (Therapeutic Study of ONO-4819CD for Ulcerative Colitis).

Mechanism: Pharmacologically active on Prostaglandin E2 receptor EP4 subtype and Prostaglandin E2 Receptors
Curator reviewed
Formula / weight: C₂₄H₃₄O₆S · 450.59 g/mol (avg)
Code names: (-)-ONO-4819

Resolves to

Compound

Structure

InChIKeyFBQUXLIJKPWCAO-AZIFJQEOSA-NSMILESCOCC1=CC=CC(C[C@H](O)\C=C\[C@H]2[C@H](O)CC(=O)[C@@H]2CCSCCCC(=O)OC)=C1

Targets

What you can answer from here — as of May 05, 2022

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rivenprost, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.